ANI Pharma (ANIP) Misses Q4 EPS by 20c

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $0.54, $0.20 worse than the analyst estimate of $0.74. Revenue for the quarter came in at $60.9 million versus the consensus estimate of $56.3 million.

GUIDANCE:

ANI Pharma sees FY2022 revenue of $260-275 million, versus the consensus of $301.6 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance